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Introduction specific manner. The same two stages in cell-mediated
Transplantation research has provided many insights immunity were also observed in responses to nominal
into fundamental aspects of immunology, including the antigens, particularly in the induction of the primary anti-
biology of dendritic cells (DCs). The critical tools of body response (reviewed in Steinman, 1991).
transplantation research—antibodies to major histo- Strong staining for MHC class II and an absence of
compatibility complex (MHC) class I and II products, the B cell or macrophage markers were used to search for
mixed leukocyte reaction (MLR), and rodent experimen- DCs in situ. In tissue sections from rats and humans,
tal models of skin and organ transplantation—were vital MHC class II–positive DCs were identified in the intersti-
to the initial characterization of DCs as distinct leuko- tial spaces of all organs examined except the brain pa-
cytes, specialized to initiate graft rejection (reviewed in renchyma. In lymphoid tissues, DCs are abundant in the
Steinman, 1991). It was proposed that bone marrow– T cell areas of spleen and lymph nodes and the medulla
derived DCs in the allograft were the foes responsible of the thymus. The same criteria were used to identify
DCs in human blood and in afferent lymph from manyfor immunogenicity. An oversimplified concept arose
species, but DCs were absent in efferent lymph. Whenthat DC elimination, something that is very difficult to
isolated DCs were reinfused into rodents, the DCs mi-achieve, would lead to graft acceptance. In fact, the
grated to the T cell areas of the draining lymphoid organ.situation is far more complicated. DCs in both the graft
After antigen administration by intramuscular or intrave-donor and the recipient can act as the foe, stimulating
nous routes, the DCs in the lymph and spleen were therejection by what are termed the direct and indirect
main cell type able to present antigen to T cells. Thepathways, respectively. However, there is also emerging
concept arose that DCs could pick up antigens in theevidence that DCs can act as a friend, promoting graft
periphery and migrate to the T cell areas (in spleen viaacceptance. More broadly, the studies of DCs in trans-
the blood, in lymph nodes via the lymph), where theyplantation are valuable for understanding their role in
could either initiate an immune response to the antigensimmunity to other antigens and, recently, in peripheral
that the DCs were presenting or simply die (Figure 1).tolerance. This review addresses some potential roles of
As we will consider below, death is followed by re-pre-DCs in transplantation in the light of current knowledge
sentation of proteins in the dying DCs by resident DCconcerning DC biology, immunity to alloantigens, and
in the lymph node. In transplant models, DCs derivedperipheral T cell tolerance.
from transplanted allogeneic tissues and carrying donor
MHC antigens could be identified in the peripheral
Some Features of DCs lymphoid tissues of graft recipients. Further, many stud-
DCs were first distinguished from other white blood cells ies with nominal antigens showed that injections of anti-
on the basis of their distinctive cell shape and an ab- gen-charged DCs initiated T cell–mediated immunity,
sence of critical lymphocyte and phagocyte properties. including protective antimicrobial and antitumor immu-
When these criteria were used to enrich DCs from differ- nity. When tested, the T cell response was restricted to
ent tissue sources, a high level of antigen-presenting antigens presented by the MHC products of the injected
MHC products, especially MHC class II (.106 molecules/ DCs and not to the recipient’s antigen-presenting cells,
cell when measured), was always noted. The capacity indicating that DCs could directly stimulate recipient T
of T cells to respond to MHC products on DCs was cells. In sum, the distribution and migration of DCs in
tested in the MLR. The DCs proved to be remarkably vivo (Figure 1) correlated closely with their capacity to
potent, at least 100 times more active than MHC class mediate the afferent phase of cell-mediated immunity
II–bearing macrophages and B cells. Indeed, the MLR (reviewed in Steinman, 1991).
DCs are continuously produced in the bone marrow,
undergoing considerable turnover in most tissues ex-‡ To whom correspondence should be addressed (e-mail: r.lechler@
ic.ac.uk). cept the epidermis. Immature DCs and their precursors
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Figure 1. Distribution and Migration of Dendritic Cells
(1) Proliferating DC progenitors in the bone marrow release precursor and immature forms of DC into the blood.
(2) Precursors to DC in the blood migrate to peripheral tissues.
(3) Immature DC capture pathogens and self-antigens from the tissue.
(4) Antigen-loaded DC enter afferent lymphatics or the blood and thereby migrate to secondary lymphoid tissue; this process may be
accompanied by maturation upon receipt of appropriate stimuli.
(5) Tissue DC present MHC-peptide (black circles) complexes to antigen-specific T cells in the secondary lymphoid organs.
are always trafficking through tissues in the steady state, being produced just in case infection should arise.
Rather, DCs in the steady state may have a secondin the absence of infection or inflammation, and then
dying in the lymphoid organs. In the airways, for exam- role—transporting antigens from the periphery for the
purpose of inducing and/or maintaining peripheral toler-ple, DCs have a half-life of ,2 days (Holt et al., 1994).
When afferent lymphatics have been cannulated in the ance in the draining lymph node (Kurts et al., 1997a;
Huang et al., 2000). This will be discussed in more detaillimbs of sheep and humans, a flux of several thousand
DCs per hour is noted, as is also the case with other below.
The mechanisms underlying the immunogenicity oflymphatics in rodents. Recent studies of the turnover of
DCs in lymphoid tissues reveal half-lives of 1.5–3 days DCs are beginning to be unravelled. The DCs in blood
and tissues prove to be immature, not fully differentiated(Kamath et al., 2000)—even faster than the earliest mea-
surements on the life span of these cells. Beyond the to act as potent stimulators of immunity. The first exam-
ple was the Langerhans cell in the epidermis (Schulerbone marrow, several possibly distinct sources of DCs
are found in the blood (Table 1). However, the continued and Steinman, 1985). Immature DCs can capture soluble
and particulate antigens, especially by receptor-medi-production and traffic of DCs in the steady state are not
really analogous to granulocytes, which are constantly ated pathways. Their MHC class II products lie primarily
Table 1. Bone Marrow–Derived Dendritic Cell Precursors in the Blood
Precursors Stimuli for DC Development
Monocytes (CD141, CD11c1) GM-CSF and IL-4 followed by maturation stimuli
(TNF, IL-1, CD40L, LPS, CpG oligos, necrosis)
reverse migration across endothelia, possibly lymphatics
particle uptake during inflammation
Plasmacytoid cells (CD142, CD11c2) enveloped viruses
CD40L and IL-3
CpG oligos





within MHC class II–positive endocytic vacuoles that both. The recognition events that lead to the vigor of
responses observed when MHC-incompatible cells arealso contain HLA-DM molecules, which facilitate the
binding of high-affinity peptides. During maturation, cocultured are referred to as the “direct” pathway of
allorecognition. This involves the ligation of T cell recep-MHC peptide complexes begin to form within the MHC
class II– and HLA-DM-positive compartments, followed tors on alloreactive T cells by foreign MHC molecules,
intact, on the surface of allogeneic cells. It was notedby transport in nonlysosomal vesicles to the cell surface
in large amounts (Pierre et al., 1997). Several costimula- several decades ago that underlying this strength of
proliferative response was a uniquely high frequency oftory molecules are also expressed, with especially high
levels of CD86. The MHC-peptide complexes are found T cells with direct allospecificity. Evidence from a variety
of sources, including a recent structural analysis of anin clusters at the DC surface together with CD86 (Turley
et al., 2000). It is postulated that these high levels of alloreactive TCR (Daniel et al., 1998), indicates that this
mode of allorecognition results from cross-reactivity byantigen-presenting and costimulatory molecules, in a
clustered distribution, initiate the formation of the immu- T cells specific for a self-MHC molecule, “A,” with pep-
tide “x” on an allogeneic MHC molecule, “B,” with pep-nologic synapse, bringing together essential elements,
like the T cell receptor (TCR) and CD28, that are required tide “y.” At face value, the recognition of allogeneic MHC
breaks the rules of thymic positive selection for self-for T cell activation. Furthermore, mature DCs cease
many of their endocytic activities, most likely accounting MHC restriction. However, the structural similarity be-
tween the TCR contact surfaces of many MHC allelesfor the longevity of MHC-peptide complexes at the cell
surface. Maturing DCs change in many other ways, in- allows a substantial fraction of direct alloresponses to
be accommodated within the framework of positive se-cluding the production of cytokines like IL-12 and a
reshaping of their chemokine receptors, the latter con- lection. In responder–stimulator combinations in which
such structural similarities apply, allorecognition can betributing to their migration to the T cell areas of lymphoid
tissue (Cyster, 1999; Sallusto and Lanzavecchia, 1999). regarded as mimicking self-MHC restriction and as di-
rected against novel peptides that are bound by theMultidrug transporters, by pumping cysteinyl leuko-
trienes, are newly recognized intermediaries for DC mat- allogeneic but not the self-MHC molecules due to differ-
ences in the peptide binding groove (Lechler et al., 1990).uration and migration in vivo (Robbiani et al., 2000).
Maturation stimuli for DC development comprise in- In combinations in which there are multiple amino acid
differences in the TCR contact surfaces, the allore-flammatory cytokines (TNFa, IL-1), microbial products
(LPS, CpG deoxyoligonucleotides), and CD40L on acti- sponse is likely to result from a chance higher affinity
cross-reaction with the foreign MHC structure. Givenvated T cells, platelets, and mast cells. Many of these
maturation stimuli act on receptors that trigger NF-kB the bias that appears to exist in TCR genes for MHC
recognition (Merkenschlager et al., 1997), this is likelyactivation via the TNF receptor–associated factor TRAF
6. Receptors for maturation include IL-1R, TNF-R family to occur in structurally dissimilar responder–stimulator
combinations with sufficient frequency to account formembers, and Toll receptors or TLRs. However, the act
of transplantation itself appears to trigger the maturation the numbers of alloreactive T cells identified by limiting
and migration of DCs (Larsen et al., 1990), although dilution analysis assays.
the responsible stimuli are not yet known. CD40 is an It has long been assumed that acute transplant rejec-
intriguing player, since, in CD40L knockout mice, DCs tion represents the in vivo correlate of the in vitro MLR;
are unable to migrate during contact allergy, another however, little evidence has been produced in support
powerful T cell response in which DCs also mature and of this contention. Evidence that T cells with exclusively
migrate to draining lymph nodes. In both transplantation direct allospecificity can affect transplant rejection was
(Barker and Billingham, 1968) and contact allergy (Frey provided in a very recent study. Reconstitution of severe
and Wenk, 1957), the severing of afferent lymphatics combined immunodeficiency (SCID) or Rag12/2 mice
reduces sensitization in response to skin grafts and al- with syngeneic CD41 T cells led to rejection of MHC
lergens, suggesting that DC traffic is critical for immuni- class II–expressing cardiac allografts but not MHC class
zation. Studies in corneal transplantation lend further II–deficient grafts. Furthermore, Rag12/2 mice that were
support to these concepts, in that the likelihood of cor- also MHC class II deficient rejected allogeneic cardiac
neal allograft rejection was observed to correlate with transplants when reconstituted with CD41 T cells. Since
the DC content of the transplanted tissue (Niederkorn, these mice have no CD81 cells and lack the capacity
1999). In addition, TNF mRNA was induced, even in for MHC class II–restricted indirect allorecognition (see
syngeneic grafts, due to the trauma of surgery, providing below), these results indicate that direct pathway CD41
a maturation signal for local DCs (King et al., 2000). T cells were both necessary and sufficient to mediate
In summary, DCs are centrally involved in the initiation allograft rejection (Pietra et al., 2000).
of T cell–dependent immune responses, such as trans- The Indirect Pathway of Anti-MHC Allorecognition
plant rejection. The roles of donor and recipient DCs and Transplant Rejection
and their contributions to sensitization and to the induc- The alternative pathway of allorecognition is referred to
tion of tolerance in the two pathways of allorecognition as the indirect pathway. This results from the recognition
are discussed separately below. of allogeneic MHC molecules, predominantly MHC mol-
ecules, as peptides, presented in the context of self-
MHC (Figure 2). Given that this corresponds to the man-Contributions of Direct and Indirect Pathways of
Anti-MHC Allorecognition to Transplant Rejection ner by which T cells recognize all other nominal antigens,
the term “indirect” may be misleading; however, itThe Direct Pathway
MHC alloantigens can be recognized by T cells via two serves to contrast this mode of allorecognition with the
direct pathway. In fact, MHC peptides are quite fre-distinct pathways, and DCs are likely to be central to
Immunity
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Figure 2. Direct and Indirect Allorecognition
(Indirect allorecognition) Alloantigens are shed from the donor cell surface or are taken up as dying allogeneic cells by host antigen-presenting
cells (e.g., immature DCs). In the latter, peptides derived from allogeneic MHC molecules are re-presented on the self-MHC molecules (black
circles), especially MHC class II, of the recipient antigen-presenting cells, much like conventional antigens. Helper cells recognizing donor
MHC class I or II peptides on responder MHC then help the formation and function of CD81 CTL that directly recognize donor allogeneic MHC
molecules (e.g., by releasing IL-2 or other cytokines). (Direct allorecognition) Recipient T cells engage with complexes of intact allogeneic
MHC molecules and bound peptides (striped circles) on the surface of donor cells.
quently eluted from the peptide binding grooves of MHC grafts enjoyed prolonged if not indefinite survival (Tal-
mage et al., 1976; Bowen et al., 1980). This highlightedmolecules (Rudensky et al., 1991; Chicz et al., 1993).
The most striking demonstration of the propensity of the distinction between antigenicity (the capacity to be
recognized) and immunogenicity (the capacity to induceMHC molecules to be presented in peptide form by other
MHC molecules involved Y-Ae, the first monoclonal anti- an effective immune response). Their interpretation of
these findings was that bone marrow–derived cells werebody that was shown to be specific for an MHC-peptide
complex. This antibody sees a peptide fragment from both antigenic and immunogenic, while the parenchymal
cells of the graft were merely antigenic. The finding inthe H2-Ea chain (highly conserved in homologous genes
from rat and human) presented on H2-Ab products (Ru- the rat kidney model was that, in certain strain combina-
tions in which primary kidney allografts were rapidlydensky et al., 1991). The corresponding MHC-peptide
complex is expressed at high levels on DCs and B cells rejected, retransplanted grafts that had been “parked”
in an intermediate recipient for 1 month or more underfrom strains expressing H2-Ab and H2-E but not from
strains expressing H2-Ab alone or H2-E with other H-2A the cover of immunosuppression were spontaneously
accepted without any exogenous immunosuppressionalleles. The high level of staining obtained with this anti-
body illustrates the capacity of MHC molecules to pres- (Lechler and Batchelor, 1982a). The relevance of DCs
to these findings is discussed below. One of the strainent MHC-derived peptides. This has also been demon-
strated in the DCs of the thymic medulla, an important combinations in which retransplanted kidney grafts
were accepted without exogenous immunosuppressionsite for the development of thymic or central tolerance
by negative selection. was (AS 3 AUG) F1 into AS. However, if the strain combi-
nation was changed and fully allogeneic AUG donorsThe original proposition that a second pathway of
allorecognition exists and can contribute to transplant were used, the retransplanted grafts were invariably re-
jected, albeit at a slower tempo. Based on the assump-rejection arose from a DC depletion experiment involv-
ing rat kidney transplantation (Lechler and Batchelor, tion that the parenchymal tissues of the kidney were
incapable of activating direct pathway antidonor T cells,1982a). These studies were based on the pioneering
experiments of Lafferty and colleagues, who performed it was proposed that a second, indirect, pathway of
allorecognition was responsible for T cell sensitization.a series of transplants using thyroid or pancreatic islet
tissues that had been depleted of bone marrow–derived Since the existence of the indirect pathway was first
proposed, a large literature has accumulated illustratingcells by in vitro culture. They noted that the depleted
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that this pathway can cause transplant rejection (re- One involves offering donor MHC molecules as synthetic
viewed in Auchincloss and Sultan, 1996). A comprehen- peptides, thereby bypassing the need for antigen pro-
sive series of experiments has been performed by Au- cessing. Three groups have reported raised frequencies
chincloss and colleagues using MHC class I and II of T cells with indirect antidonor specificity in patients
knockout donor and recipient mice. Their most compel- with chronic heart (Liu et al., 1996), kidney (Vella et al.,
ling evidence that the indirect pathway is sufficient to 1997), and lung (SivaSai et al., 1999) transplant rejection.
mediate transplant rejection was the observation that The other approach that has been used involves offering
MHC class I knockout recipient mice could reject skin donor antigens in the form of lysed whole cells, thereby
grafts from MHC class II knockout donor mice (Grusby making no assumption as to which peptides will be rec-
et al., 1993). The recipient mice lacked CD81 cytotoxic ognized. Using this approach, we have detected raised
T cells capable of recognizing donor MHC class I mole- frequencies of indirect pathway T cells in patients with
cules directly, and the CD41 T cells in the recipient but not without chronic heart transplant rejection (Hor-
animals could only be stimulated by recognizing donor nick et al., 2000).
MHC class I molecules indirectly, presented in the con- If the indirect pathway is critical in mediating trans-
text of recipient MHC class II molecules. plant rejection, it follows that abolition of the direct path-
Returning to the original experiments with donor DC- way alone will not achieve allograft tolerance. More im-
depleted kidney grafts, in the strain combinations in portantly, strategies that promote tolerance in the
which rejection occurred, the tempo was invariably indirect pathway should enhance allograft survival. One
slower, with a mean rejection time of 21 versus 10 days strategy that has been employed to avoid direct pathway
for DC-replete grafts. This was the basis for suggesting sensitization is to use, as donors, animals chimeric for
that the indirect pathway might be most prominent in recipient bone marrow. Krasinskas et al. created such
later, more chronic forms of rejection. The hypothesis bone marrow chimeras in mice and rats. This led to
that T cells with indirect antidonor allospecificity are prolongation of graft survival in all cases, although the
important drivers of chronic transplant rejection has re- extent of the effect varied between different strain com-
ceived support from several clinical studies. binations. Despite this, allograft vasculopathy, an indi-
First, it appears that the strength of the direct antido- cation of chronic rejection, occurred in all recipients
nor alloresponse diminishes with time after transplanta- (Krasinskas et al., 2000). Although APC-depleted kid-
tion. In renal and cardiac transplant patients, the fre- neys and skin grafts were rejected, APC-depleted islet
quencies of antidonor CD41 T cells proliferating and grafts were accepted permanently without immunosup-
secreting cytokines in response to donor cells is sub- pression. It would appear at first sight that this was
stantially reduced compared with frequencies measured due to the lack of direct pathway stimulation; however,
against third-party cells (Mason et al., 1996; Hornick et Coulombe and coworkers recently showed that the tol-
al., 1998). A similar fall in the frequencies of CD81 T erance in such a model is CD41 T cell dependent (Cou-
cells has been documented. This is likely to reflect the lombe et al., 1999). Since these islet grafts were essen-
consequences of alloantigen presentation by the nonim- tially negative for MHC class II expression, this implied
munogenic parenchymal cells of the transplanted tissue. that the tolerance was maintained through the indirect
Indeed, culture of CD41CD4RO1 T cells with HLA-mis- pathway. Compelling evidence that induction of toler-
matched, g-interferon-treated primary epithelial cell cul- ance in the indirect pathway favors graft survival came
tures from human thyroid or kidney induced allospecific from experiments in which recipient animals were pre-
hyporesponsiveness (Marelli-Berg et al., 1997; Frasca treated with donor MHC peptides. The peptides were
et al., 1998). If this is the correct explanation for the administered either intrathymically (Chowdhury et al.,
decline of the direct antidonor alloresponse, the trans- 1996) or orally (Zavazava et al., 2000) or as donor pep-
plant-induced hyporesponsiveness should be most pro- tide-pulsed recipient APCs (Ali et al., 2000). All of these
nounced in the CD45RO1 T cell population, in that allore-
treatments induced graft prolongation. Although the
active T cells of this phenotype are the ones that can
mechanisms of these strategies have not been defined,
cross the donor endothelium and enter the graft. We
the use of donor peptides means that the enhancementhave recently tested this prediction by measuring anti-
of graft survival can only be mediated through the indi-donor and anti-third-party frequencies in CD45RA1 and
rect pathway. Equally interesting is the finding, in a mu-CD45RO1 T cells at the time of transplantation and 4
rine skin allograft model, that tolerance cannot be in-months later. A significant fall in antidonor frequency
duced in the absence of the indirect pathway. In thiswas only seen in the RO1 T cell fraction, in keeping with
model, if normal MHC-mismatched skin was trans-a role for transplant parenchymal cell antigen presenta-
planted onto normal recipients, treatment with anti-tion in limiting the activity of the direct pathway response
CD40L, CTLA-4-Ig, and anti-CD8 led to long-term skinwith time (Baker et al., 2001). Perhaps most significantly,
graft survival. Furthermore, the recipients became toler-the decline in the direct response was equally pro-
ant, as evidenced by the ability of their T cells to protectnounced in patients with classical features of chronic
a fresh skin graft from the same donor strain followingrejection as in those with stable good function (Mason
adoptive transfer. In contrast, if the response was con-et al., 1996; Hornick et al., 1998). This finding suggests
fined to the direct pathway, due to the use of the so-that the direct pathway of antidonor alloreactivity is not
called II241 mice as recipients (these mice express MHCan important driver of chronic rejection.
class II molecules only in the thymus and not on periph-The second series of clinical data comes from at-
eral APC) and if the same immunosuppressive protocoltempts to measure the indirect pathway in patients with
was used, all the grafts were rejected (Yamada andestablished chronic rejection. Two approaches have
been taken to reveal T cells with indirect alloreactivity. Auchincloss, personal communication). This suggests
Immunity
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that tolerance in the indirect pathway may be required to spontaneously accepted, without immunosuppression,
inhibit direct pathway T cells and to maintain tolerance. donor irradiation led to liver graft rejection (Sun et al.,
1995). Although the possibility was not fully excluded
that donor irradiation modified the graft in some deleteri-
The Role of Donor Dendritic Cells in Transplant ous way—altering vascular permeability, for example—
Rejection or Tolerance these results probably indicate a need for donor leuko-
At face value, the contribution of DCs to transplant rejec- cytes in the induction of tolerance.
tion may seem quite straightforward within this frame- Given the key role of the indirect pathway of allorecog-
work of direct and indirect allorecognition. Donor DCs nition in transplant rejection and in transplantation toler-
initiate direct pathway responses, and recipient DCs ance, these results do not necessarily challenge the
initiate the activation of T cells with indirect allospecific- importance of the donor DC in priming direct pathway
ity. Indeed, these were the concepts that grew out of T cells. Rather, they may highlight the possibility that
the original “passenger cell” observations. As outlined the donor DC, due to its propensity for migrating to
above, the seminal finding was that depletion of donor draining lymph nodes, can provide a source of donor
leukocytes led to prolonged allograft survival. A variety antigen, in the lymph node, for the induction of tolerance
of methods was used to deplete leukocytes, although, in T cells with indirect allospecificity. Support for this
at the time, reagents such as monoclonal antibodies concept is provided by further experiments using the
were not available to monitor and identify the types Y-Ae monocloncal antibody to monitor the processing
of depleted cells, distinguishing, for example, between and presentation of H2-Ea in vivo. When H2-E-bearing
tissue macrophages and tissue DCs. Lafferty used low- DCs were injected into H2-Ab recipients, within 2 days
temperature culture or culture in hyperbaric oxygen to most of the recipient DCs in the draining lymph node
kill off passenger cells while preserving the viability of became reactive with Y-Ae. The number of donor cells
the tissue parenchymal cells. He applied these tech- in the lymph node was very much smaller than the num-
niques to thyroid and pancreatic transplants (Talmage ber of recipient DCs that had processed the donor H2-E
et al., 1976; Bowen et al., 1980). The rat kidney graft (Inaba et al., 1998). This result implies that, when migra-
experiments involved parking the kidney in an intermedi- tory donor DCs die upon reaching the lymph node, they
ate recipient under the cover of immunosuppression.
are phagocytosed and processed by resident recipient
Support for the concept that the lack of rejection of
DCs. However, these experiments have yet to elucidate
these retransplanted grafts was due to the loss of immu-
if cross-presentation by DCs leads to immunity (cross-
nogenic donor bone marrow–derived APC came from
priming) or specific unresponsiveness (cross-tolerance)the finding that injection of as few as 104 donor strain
(Figure 3).DC at the time of retransplantation led to brisk rejection
This interpretation of the role of the donor DC does(Lechler and Batchelor, 1982a). Furthermore, if the inter-
not immediately resolve the conflicting data as tomediate recipient was made into a bone marrow chimera
whether they are “friends” or “foes” of the transplantedwith donor strain bone marrow after acceptance of the
tissue. However, in the models where donor leukocytesprimary graft, the retransplanted grafts were rejected
are required for the expression of tolerance induced byas promptly as the primary graft would have been in the
prior antigen exposure, donor DCs may be required toabsence of immunosuppression (Lechler and Batchelor,
amplify indirect pathway regulatory cells primed by the1982b).
earlier antigen treatment. In the case of spontaneouslyThe most intuitive interpretation of these experiments
accepted liver grafts, the explanation may lie with thewas that the donor DC made a vital contribution to sensi-
particular properties of Kuppfer cells, a liver-specifictization of the direct pathway and that, in their absence,
population of leukocytes, or, indeed, with the tolerance-the fate of the tissue depended upon the strength of
promoting effects of the liver itself. It is also possiblethe indirect pathway, which would be predicted to be
that distinct subsets of tolerogenic DCs exist and thatunder classical Ir gene control. However, the assump-
they are differentially distributed in different organs.tions underlying this interpretation were not tested. For
Another set of data that relate to the role of donor DCexample, it would be predicted that a DC-depleted graft
in transplant immunity concerns the phenomenon ofwould cause little amplification of the direct response,
donor microchimerism, as observed by Starzl and co-while a DC-replete graft would induce an increased fre-
workers. They have described the detection of donorquency of T cells with direct antidonor allospecificity.
cells in a variety of peripheral sites and in the thymusMeasurement of direct and indirect pathway sensitiza-
of recipient animals and in patients, following organtion was not undertaken in these studies.
transplantation. This has been most pronounced in re-In apparent contradiction to the classical passenger
cipients of liver grafts, not surprisingly, due to the largercell experiments, a series of groups have reported that
load of bone marrow–derived cells cotransplanted withdepletion of donor bone marrow–derived cells prevents
a liver. It has been argued that the seeding of recipientthe induction of transplantation tolerance. For example,
tissues with such donor cells is instrumental in the in-Cuturi noted that depletion of passenger leukocytes
duction of donor-specific tolerance for donor antigensfrom rat donor heart allografts reversed the beneficial
(Starzl et al., 1996). Two major issues remain unresolvedeffects of donor-specific blood transfusion. Further-
regarding this hypothesis. First, it is unclear whether themore, tolerance was reestablished if donor-type DCs
persistence of donor leukocytes in tolerant recipientswere cotransferred at the time of transplantation of APC-
represents cause or effect. If the recipient has becomedepleted cardiac grafts (Josien et al., 1998). Similarly,
using rat strain combinations in which liver allografts are tolerant to donor alloantigens, this is likely to favor the
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Figure 3. Roles of Donor and Recipient Dendritic Cells in Direct and Indirect Allorecognition
(1) The graft contains donor DCs (black) as well as recipient immature DCs (white).
(2) Recipient DCs that have captured antigens from the graft (e.g., dying cells) enter the lymph, much like donor graft-derived DCs.
(3) In the recipient lymph nodes, donor DCs and recipient DCs can stimulate the direct and indirect pathways of allorecognition. In addition,
donor DCs can die in the lymph node, and their MHC products can be processed widely by the recipient DCs.
(4) As a result of (3), many more recipient DCs in the lymph nodes are able to capture and present donor peptides to indirect allospecific
recipient T cells.
persistence of long-lived donor cells that would other- al., 1999) suggest that DCs are peculiarly differentiated
to cross-present antigens on MHC class I.wise be destroyed. Second, it is not clear whether mi-
crochimerism is a mechanism for the induction of toler- The processing of MHC class II donor alloantigens
has primarily been studied using the Y-Ae antibody spe-ance in the direct or the indirect pathway.
cific for the H2-Ab-Ea peptide complex as described
above. Dead H2-E1 donor B cells were fed to DCs thatThe Role of Recipient Dendritic Cells in Transplant
expressed H2-Ab, and indirect presentation was moni-Rejection or Tolerance
tored by the development of the epitope recognized byThere can be little doubt that a major contribution of
the Y-Ae antibody. The H2-Ab DCs became reactive withthe recipient DC to transplant rejection is by sensitizing
Y-Ae, and the processing was sensitive to a blockadeT cells with indirect antidonor specificity. A variety of
of proteolysis with ammonium chloride. The indirectexperimental models have been designed to examine
pathway was unusually efficient in DCs. If one estimatedthe pathways whereby DCs could stimulate the indirect
the amount of H2-E protein in the dead cells that werepathway of rejection. The mechanism that leads to indi-
offered to the DCs and compared this to the amount ofrect allosensitization involves the internalization and
H2-E peptide giving rise to the same amount of MHCprocessing of proteins from dead or dying donor cells
peptide complex (Y-Ae epitope), the dead cells wereand subsequent presentation by the MHC products of
several thousand times more effective as a source ofa recipient DC. Immature DCs are able to phagocytose
antigen (Inaba et al., 1998). Interestingly, the sequenceapoptotic and necrotic cells and then present peptides
of the relevant H2-E peptide is conserved in HLA-DRa,on both MHC class I and II products (Albert et al., 1998;
and human B-LCL could also be processed by mouseInaba et al., 1998; Sauter et al., 2000). Successful pre-
DCs to form the Y-Ae epitope. In ongoing experiments,sentation requires that the DCs mature after the initial
DCs are proving to be the main cell type in spleen thatuptake step (Albert et al., 1998; Inaba et al., 1998). Mono-
cross-presents H2-E protein when dead B cells are in-cytes are, if anything, more phagocytic than mature DCs
jected intravenously. Likewise, a recent report showsbut seem to thoroughly degrade the ingested proteins
that DCs are the main cell type that cross-presents cell-rather than resurrect peptides from the dead cells (Albert
associated donor proteins (in this case, ovalbumin) onet al., 1998). B cells, to date, are poor at cross-presenta-
MHC class I products (den Haan et al., 2000). The impli-tion (Munz et al., 2000). This may in part be due to limited
cation of these experiments is that, whenever dead cellsphagocytic activity, but studies with different antigen-
presenting cell lines (Regnault et al., 1999; Rodriguez et are cleared from a graft via the blood or lymph, the MHC
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products from the dead cells might undergo efficient Based on current knowledge of DC biology, this is pre-
dictable; surgeons are “dangerous,” and the trauma ofprocessing and presentation by the recipient DCs.
surgery and ischemia–reperfusion injury will invariablyAs stated earlier, a tissue DC requires a maturation
provide the maturation signals that tissue DC may re-signal in order to become immunogenic. Such signals
quire in order to migrate and induce T cell activation.can be provided by invading pathogens or tissue inflam-
The possible exception to this generalization is the liver,mation or injury (Janeway, 1992; Matzinger, 1994). One
based on the irradiation experiments mentioned above.difficulty with this “danger” theory is that it does not
Nonetheless, it is not clear that elimination/inactivationresolve a new view of the self–nonself dilemma that
of DCs is responsible for the beneficial effects of donorhas emerged from studies of DC maturation. During
irradiation, and Kupffer cells and sinusoidal lining cellsinfection—when DCs phagocytose dying infected cells,
(Limmer et al., 2000) may well be important contributorsas well as proteins, in the infected environment, such
to these events.as the lung or gut—how do the DCs selectively present
However, new research suggests that circumstancesmicrobial proteins and not proteins from dying self-tis-
can be created in which DCs can be considered assue or the environment? For this reason, it has been
friends capable of inducing peripheral tolerance. Asproposed (Steinman et al., 2000) that, in the steady state,
summarized above, donor DCs may be required for theDCs have the capacity to tolerize the T cell repertoire
development of tolerance induced by donor antigen pre-peripherally to those self and environmental proteins
treatment (Josien et al., 1998), and exposure to immature
that are readily processed. These proteins would be
DCs can prolong graft survival.
captured during the traffic of DCs through the tissues
Thomson’s group has explored this possibility in de-
and lymph, especially from cells dying through the nor- tail. They injected mice with allogeneic DCs, but they
mal process of cell turnover. Uptake of dying intestinal did so at the immature stage of development. A modest
epithelial cells has been observed in DCs trafficking in prolongation of graft survival was observed, and this
rat mesenteric lymph (Huang et al., 2000), and a subset was specific, since it was not seen following a challenge
of DCs in the lymph seems to be preferentially involved. with third-party grafts (Fu et al., 1996). In experiments
Possibly, a subset of DCs, as proposed for CD81 mouse where DCs have been used to immunize mice with nomi-
spleen DCs by Shortman (Kronin et al., 1996), have a nal antigens, mature DCs have been much more immu-
tolerizing or regulatory role. Likewise, several labora- nogenic than immature DCs (Stumbles et al., 1998; Inaba
tories (Forster and Lieberam, 1996; Kurts et al., 1997a; et al., 2000; Schuurhuis et al., 2000). However, the stud-
Adler et al., 1998; Morgan et al., 1999) have shown that ies in transplantation raised the possibility that immature
bone marrow–derived cells in the lymph node (possibly DCs were not simply ignored but could be actively toler-
DCs) can tolerize T cells, by deletion or anergy, to anti- ogenic. Likewise, studies on the presentation of self
gens cross-presented from nonhematopoietic cells. (Forster and Lieberam, 1996; Kurts et al., 1997a; Adler
This tolerance is delicate. In the experiments of Kurts et al., 1998; Morgan et al., 1999) antigens in mice have
et al., an infusion of CD41 helper cells broke the toler- shown that bone marrow–derived cells are capable of
ance of CD81 T cells (Kurts et al., 1997b). In a recent mediating peripheral tolerance by cross-presentation of
self or tumor antigens. In these experiments, self- andstudy by Bingaman et al., where a large number of T
tumor-reactive CD41 and CD81 T cells could be deletedcells or thymocytes were introduced into nude animals
(Kurts et al., 1997a) or anergized (Forster and Lieberam,bearing well-healed allografts, rejection was readily in-
1996; Adler et al., 1998) upon encounter of antigens induced in the ostensible absence of danger (Bingaman
the steady state, under “noninflammatory” conditions.et al., 2000). Perhaps these data can be reconciled by
An alternative mechanism for transplantation toler-proposing that DCs in the steady state, in the absence
ance has emerged from in vitro studies of the MLR,of maturation stimuli, only have the capacity to silence
using DCs at an immature stage of differentiation. Again,and/or regulate small numbers of low-affinity T cells
it has been repeatedly observed that immature DCs arespecific for self-peptides. If the number of T cells ex-
weak stimulators of the MLR, but recent data have signif-ceeds a certain limit (as in Kurts’ experiments) or are
icantly extended these findings (Jonuleit et al., 2000).of higher affinity (as in Bingaman’s experiments), the
Alloreactive CD41 cells of the Th1 type developed whentolerogenic effects of immature DCs may be overridden.
mature DCs were used as stimulators. However, whenThe implication of all of these observations is that
immature DCs from the same donor were used to stimu-
the indirect pathway of allorecognition is driven by the
late the same allogeneic T cells, the T cells proliferated
efficient functioning of normal antigen presentation minimally, lost the capacity to be stimulated by mature
pathways. This may explain, in part, why chronic rejection DCs, and, importantly, would significantly inhibit the re-
is so refractory to conventional immunosuppression. sponses of alloreactive Th1 cells to mature DCs. There-
fore, T cells induced with immature allogeneic DCs had
a regulatory function and also produced IL-10, as has
Dendritic Cells and Transplantation Tolerance been seen with cloned T regulatory cells. The mecha-
Returning to the question posed by the title of this re- nism of regulation in the Jonuleit et al. study also in-
view, it seems that the DC is almost inevitably a foe in volved cell–cell contact.
the context of tissue transplantation. The donor DC is A second in vivo study of regulation by immature DCs
implicated as a foe by the passenger cell depletion ex- was just reported by Dhodapkar et al., using influenza
periments conducted with endocrine and kidney grafts. viral peptide as a nominal antigen. They had shown
The recipient DC also appears to be responsible for that, when volunteers were given the peptide in saline,
antigen-reactive CD81 T cells did not expand, but, whenpriming and maintaining the indirect alloresponse.
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stimulated with peptide-pulsed mature DCs given sub- Summary
The existence of two sets of dendritic cells in trans-cutaneously, the CD81 T cells responded rapidly. In con-
trast, when immature DCs were used in two individuals, plantation (of donor and recipient origin) poses unique
problems in alloimmunity and tolerance. Donor DCs arethe peptide-reactive CD81 T cells were silenced in terms
of IFN-g production and cytolytic function, but antigen- potent stimulators of the direct pathway, in which recipi-
ent T cells respond to peptides presented on donor MHCspecific IL-10-producing CD81 T cells were now de-
tected (Dhodapkar et al., 2001). This silencing of CD81 products or to the donor MHC molecules themselves.
Reduced DC function in the direct pathway is used toeffectors by immature DCs was specific for the influenza
peptide on the DCs, since other cytomegalovirus (CMV)- explain the acceptance of certain allografts that have
been depleted of passenger leukocytes. Reciprocally,specific CD81 T cells were unperturbed.
These studies with human DCs have uncovered a po- purified donor DCs powerfully stimulate the rejection of
these grafts as well as the mixed leukocyte reaction bytential role of immature DCs in the induction of regula-
tory T cells. The findings suggest that the injection of purified allogeneic T cells in culture. Donor DCs also can
act as specialized antigen transport vehicles in cross-immature DCs, away from the site of the graft and there-
fore away from maturing inflammatory signals, may ac- priming for the indirect pathway. Here, recipient DCs
process MHC molecules from the donor. The indirecttively regulate alloreactivity. Two types of regulatory T
cells, possibly related, are under study: the Tr1 regula- pathway of rejection is actually the rule for passenger
leukocyte-depleted grafts. Furthermore, the indirecttory cells that produce high levels of IL-10 (Groux et al.,
1997) and the CD41CD251 suppressors for autoimmu- pathway seems to be the dominant alloresponse de-
tected in long-term graft recipients, both in experimentalnity (reviewed in Shevach, 2000). These populations
were both discovered in the investigation of in vivo toler- models and clinical transplantation, particularly in those
with chronic rejection. The stimulatory function of DCsance. Tr1 cells were first appreciated in the setting of
SCID bone marrow transplant recipients who were resis- in both direct and indirect pathways is regulated by their
maturation in response to inflammatory stimuli, espe-tant to graft versus host (GVH), while CD41CD251 sup-
pressors were identified as CD5 high, CD45RB, and RC cially those delivered via IL-1, TNF, and Toll receptor
families. Since the normal function of DCs is to generatelow suppressors of several autoimmune diseases in ro-
dents (Sakaguchi and Sakaguchi, 1990; Fowell and Ma- immunity against invading pathogens, the indirect re-
sponse to peptides continually derived from the alloge-son, 1993).
neic MHC molecules in a tissue allograft (a surgically
introduced “pathogen” because of the associated in-
flammation and necrosis) may be more difficult to si-Manipulating Dendritic Cells to Promote
Tolerance Induction lence. However, in addition to their allostimulatory role,
immature or in vitro–manipulated DCs also have theThe risk in using immature DC for tolerance induction
is that they may inadvertently receive maturation signals potential to downregulate direct and indirect antidonor
responses through a variety of mechanisms. Intriguingin vivo and have the opposite effect to that intended.
One solution to this problem is to manipulate the DC in new evidence shows that immature DCs can actively
induce regulatory T cells. Given the probable role ofvitro in order to inhibit its immunogenicity and potentiate
its capacity to induce tolerance. There is both in vitro the indirect pathway in driving chronic rejection, the
induction of T cell tolerance (deletion, anergy, and regu-and in vivo evidence in support of this approach. For
example, genetically engineered DC that constitutively lation), especially in those T cells with indirect antidonor
allospecificity, by the injection of immature DCs pre-express viral IL-10 (Takayama et al., 1998), TGF-b (Lee et
al., 1998), FasL (Min et al., 2000), or CTLA-4-Ig (O’Rourke transplant, could serve as a critical therapeutic strategy.
et al., 2000) can induce alloantigen-specific T cell hypo-
Acknowledgmentsresponsiveness and enhance the survival of allografts
in nonimmunosuppressed recipients. Other strategies
We would like to thank Dr. A. George and Dr. G. Lombardi for theirthat have been successful in generating “tolerogenic”
critical review of the manuscript.
DC include corticosteroids (Rea et al., 2000), vitamin D3
(Penna and Adorini, 2000), and culture with a suboptimal
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